Studies have shown that by targeting FOLR1 or MSLN alone there is a 48 to 76% likelihood of near-complete tumor elimination, and simultaneous targeting of these two proteins brings the killing of tumor cells up to 88% (5, 71, 73). Here, FOLR1 is linked to neoplasm.